Medicines For Europe Sets Out Vision For Biosimilars Reforms
Proposed Policy Priorities Outline Opportunities For Europe
Four key areas for policy reform were identified by industry association Medicines for Europe at its biosimilars conference in early April, as sector chair Isabell Remus set out the importance of removing barriers to biosimilar competition.
